Adage Capital Partners Gp, L.L.C. Otonomy, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$1.72 - $2.47 $1.72 Million - $2.47 Million	1,000,000 Added 25.0%	5,000,000 $12 Million
Q3 2021 Nov 15, 2021	BUY	$1.22 - $2.2 $610,000 - $1.1 Million	500,000 Added 14.29%	4,000,000 $7.68 Million
Q2 2021 Aug 16, 2021	BUY	$2.06 - $2.67 $3.09 Million - $4 Million	1,499,500 Added 74.96%	3,500,000 $7.81 Million
Q1 2021 May 17, 2021	BUY	$2.49 - $6.23 $2.43 Million - $6.07 Million	975,000 Added 95.08%	2,000,500 $5.1 Million
Q3 2020 Nov 16, 2020	BUY	$3.16 - $4.36 $3.24 Million - $4.47 Million	1,025,500 New	1,025,500 $4.15 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.